Zacks Small Cap Weighs in on Pharma-Bio Serv FY2025 Earnings

Pharma-Bio Serv, Inc. (OTCMKTS:PBSV) – Equities researchers at Zacks Small Cap decreased their FY2025 earnings per share (EPS) estimates for shares of Pharma-Bio Serv in a research note issued to investors on Tuesday, March 18th. Zacks Small Cap analyst B. Sorensen now anticipates that the company will earn $0.09 per share for the year, down from their prior forecast of $0.11. The consensus estimate for Pharma-Bio Serv’s current full-year earnings is $0.11 per share. Zacks Small Cap also issued estimates for Pharma-Bio Serv’s Q1 2026 earnings at $0.02 EPS, Q2 2026 earnings at $0.03 EPS, Q3 2026 earnings at $0.03 EPS, Q4 2026 earnings at $0.03 EPS and FY2026 earnings at $0.11 EPS.

Pharma-Bio Serv Price Performance

OTCMKTS:PBSV opened at $0.40 on Thursday. The business’s 50-day simple moving average is $0.55 and its 200-day simple moving average is $0.56. Pharma-Bio Serv has a fifty-two week low of $0.31 and a fifty-two week high of $0.89. The stock has a market capitalization of $9.17 million, a PE ratio of -13.33 and a beta of 0.53.

Pharma-Bio Serv (OTCMKTS:PBSV) last announced its quarterly earnings results on Monday, March 17th. The company reported $0.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.35. The company had revenue of $2.47 million during the quarter, compared to analyst estimates of $2.70 million. Pharma-Bio Serv had a negative net margin of 8.18% and a negative return on equity of 5.61%.

Pharma-Bio Serv Dividend Announcement

The business also recently declared a dividend, which was paid on Thursday, March 20th. Stockholders of record on Friday, February 28th were issued a $0.075 dividend. The ex-dividend date was Friday, February 28th. Pharma-Bio Serv’s dividend payout ratio (DPR) is presently -375.00%.

Pharma-Bio Serv Company Profile

Pharma-Bio Serv, Inc operates as a compliance and technology transfer services consulting firm in Puerto Rico, the United States, Europe, Brazil, and internationally. The company provides technical compliance consulting services comprising regulatory compliance, validation, technology transfer, engineering, project management, and process support for the pharmaceutical, chemical manufacturing, biotechnology, medical device, cosmetic, food industries, and allied products companies.